Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio, Inc. (Nasdaq: ANAB) generates a steady flow of news as a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. News coverage on this page centers on its internal pipeline, royalty-bearing collaborations, corporate strategy and legal developments.
Investors following ANAB news will see updates on rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial in rheumatoid arthritis and has been evaluated in ulcerative colitis, as well as early-stage programs ANB033 and ANB101. Company announcements describe clinical data readouts, safety and efficacy findings, and decisions to advance or discontinue specific trials, such as the discontinuation of a Phase 2 ulcerative colitis study after not meeting primary and key secondary endpoints at Week 12.
Another key news theme is AnaptysBio’s financial collaborations. Releases detail royalty and milestone expectations from Jemperli (dostarlimab-gxly), the PD-1 antagonist licensed to GSK through Tesaro, and from imsidolimab, the IL-36 receptor antagonist licensed to Vanda Pharmaceuticals. Updates from partners, such as Vanda’s Biologics License Application submission for imsidolimab, also feature prominently because AnaptysBio holds the underlying license.
Corporate and capital allocation developments appear in ANAB news as well, including the company’s intent to separate its biopharma operations from its substantial royalty assets by the end of 2026 and board-authorized stock repurchase plans. Legal and regulatory items, such as AnaptysBio’s litigation with Tesaro and GSK over the Jemperli collaboration and related SEC Form 8-K filings, also contribute to the news flow. This page aggregates these announcements so readers can track how clinical results, royalty assets, strategic separation plans and legal proceedings may shape AnaptysBio’s trajectory over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AnaptysBio, a clinical-stage biotechnology firm focusing on immunology therapeutics, has appointed Dr. Rita Jain to its Board of Directors, effective immediately, following the resignation of Laura J. Hamill. Dr. Jain brings extensive expertise in rheumatology and drug development, which is expected to enhance the board’s capabilities during a critical growth phase for the company. Dr. Jain is involved in advancing immune cell modulators for autoimmune disorders, particularly in guiding Phase 2 clinical trials targeting PD-1 and BTLA checkpoint agonists. AnaptysBio’s portfolio includes several candidates in late-stage development, indicating a strong focus on addressing unmet medical needs in autoimmune diseases.
AnaptysBio, Inc. (Nasdaq: ANAB) announced significant interim results from the RUBY phase 3 trial of Jemperli (dostarlimab-gxly) for advanced endometrial cancer. The trial showed a 72% reduction in the risk of disease progression or death in the dMMR/MSI-H population, and a 36% reduction in the overall patient population. The results were published in The New England Journal of Medicine and presented at the ESMO Virtual Plenary. GSK aims for regulatory submissions in the first half of 2023. AnaptysBio anticipates potential royalties from Jemperli, particularly following these promising results.
AnaptysBio (Nasdaq: ANAB) has announced the initiation of multiple global Phase 2b clinical trials, including rosnilimab for rheumatoid arthritis in Q3 2023 and ANB032 for atopic dermatitis in Q2 2023. The company is also preparing for a second Phase 2 trial for rosnilimab, with study initiation expected by year-end 2023, and aims to file an IND for ANB033 in H1 2024. Financially, cash and investments decreased to $584.2 million, while the net loss for 2022 was $128.7 million, indicating a reduction in losses compared to the previous year. A stock repurchase plan for up to $50 million has also been authorized, set to expire at the end of 2023.
AnaptysBio, a clinical-stage biotechnology company focused on innovative immunology therapeutics, announced that interim president and CEO Dan Faga will present at the Cowen and Company 43rd Annual Health Care Conference on March 6, 2023, at 2:50 p.m. ET. The presentation will be accessible via a live audio webcast on the company’s investor website, with a replay available for 30 days post-event.
The company is working on immune cell modulators for autoimmune and inflammatory diseases, including a planned Phase 2b trial for its PD-1 agonist, rosnilimab, and BTLA agonist, ANB032. AnaptysBio’s portfolio also includes several therapeutic antibodies developed in collaboration with GSK.